Details for Patent: 12,053,463
Which drugs does patent 12,053,463 protect, and when does it expire?
Patent 12,053,463 protects REZLIDHIA and is included in one NDA.
This patent has eighteen patent family members in fifteen countries.
Summary for Patent: 12,053,463
| Title: | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| Abstract: | The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile. |
| Inventor(s): | George P. Luke, Pratik SHETH |
| Assignee: | Forma Therapeutics Inc |
| Application Number: | US18/215,727 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; |
Drugs Protected by US Patent 12,053,463
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharms | REZLIDHIA | olutasidenib | CAPSULE;ORAL | 215814-001 | Dec 1, 2022 | RX | Yes | Yes | 12,053,463 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,053,463
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Denmark | 3720442 | ⤷ Start Trial | |||
| European Patent Office | 3720442 | ⤷ Start Trial | |||
| European Patent Office | 4215197 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
